➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Boehringer Ingelheim
Mallinckrodt
McKinsey
Dow

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 10,287,353

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,287,353
Title:Combination therapies of HDAC inhibitors and PD-1 inhibitors
Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
Inventor(s): Bissonnette; Reid P. (Carlsbad, CA), Rolland; Alain (San Diego, CA), Gillings; Mireille (Las Vegas, NV)
Assignee: HUYA Bioscience International, LLC (San Diego, CA)
Application Number:16/103,865
Patent Claims:see list of patent claims

Details for Patent 10,287,353

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 001 2015-03-04   Start Trial HUYA Bioscience International, LLC (San Diego, CA) 2036-05-11 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 002 2015-03-04   Start Trial HUYA Bioscience International, LLC (San Diego, CA) 2036-05-11 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125554 001 2015-11-23   Start Trial HUYA Bioscience International, LLC (San Diego, CA) 2036-05-11 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Merck
Dow
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.